- Home
- GDL vs EDIT Comparison
GDL vs EDIT Comparison
Compare GDL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- EDIT
- Stock Information
- Founded
- GDL 2006
- EDIT 2013
- Country
- GDL United States
- EDIT United States
- Employees
- GDL N/A
- EDIT N/A
- Industry
- GDL Investment Managers
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDL Finance
- EDIT Health Care
- Exchange
- GDL Nasdaq
- EDIT Nasdaq
- Market Cap
- GDL 96.8M
- EDIT 108.1M
- IPO Year
- GDL N/A
- EDIT 2016
- Fundamental
- Price
- GDL $8.34
- EDIT $1.92
- Analyst Decision
- GDL
- EDIT Buy
- Analyst Count
- GDL 0
- EDIT 14
- Target Price
- GDL N/A
- EDIT $8.08
- AVG Volume (30 Days)
- GDL 11.2K
- EDIT 5.8M
- Earning Date
- GDL 01-01-0001
- EDIT 03-03-2025
- Dividend Yield
- GDL 6.02%
- EDIT N/A
- EPS Growth
- GDL N/A
- EDIT N/A
- EPS
- GDL N/A
- EDIT N/A
- Revenue
- GDL N/A
- EDIT $61,759,000.00
- Revenue This Year
- GDL N/A
- EDIT N/A
- Revenue Next Year
- GDL N/A
- EDIT N/A
- P/E Ratio
- GDL N/A
- EDIT N/A
- Revenue Growth
- GDL N/A
- EDIT 150.95
- 52 Week Low
- GDL $7.65
- EDIT $1.12
- 52 Week High
- GDL $8.13
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- GDL 66.71
- EDIT 55.72
- Support Level
- GDL $8.29
- EDIT $1.12
- Resistance Level
- GDL $8.37
- EDIT $3.30
- Average True Range (ATR)
- GDL 0.05
- EDIT 0.30
- MACD
- GDL 0.01
- EDIT 0.12
- Stochastic Oscillator
- GDL 82.61
- EDIT 36.70
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.